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Vitamin D, and Kidney Disease
Mineral metabolism abnormalities, such as low 1,25-dihydroxyvitamin 
D (1,25(OH)2D) and elevated parathyroid hormone (PTH), are common at 
even higher glomerular filtration rate than previously described. Levels of 
25-hydroxyvitamin D (25(OH)D) show an inverse correlation with those of intact 
PTH and phosphorus. Studies of the general population found much higher all-
cause and cardiovascular (CV) mortality for patients with lower levels of vitamin 
D; this finding suggests that low 25(OH)D level is a risk factor and predictive of 
CV events in patients without chronic kidney disease (CKD). 25(OH)D/1,25(OH)2D 
becomes deficient with progression of CKD. Additionally, studies of dialysis 
patients have found an association of vitamin D deficiency with increased 
mortality. Restoration of the physiology of vitamin D receptor activation should 
be essential therapy for CKD patients.
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diseases with increase in latitude. Additionally, serum 
25-hydroxyvitamin D (25(OH)D) levels have been shown 
to be higher in healthy subjects at lower latitudes
2). 
Vitamin D, hyperparathyroidism, and vascular 
calcification
Vitamin D plays a well-known role in the regulation 
of phosphate homeostasis. Phosphate is absorbed from 
the diet in the gut, stored in the skeleton, and excreted 
by the kidneys; 1,25-dihydroxyvitamin D (1,25(OH)2D) 
stimulates absorption of phosphate from the diet
3). 
Fibroblast growth factor (FGF)-23 increases renal 
phosphate clearance, suppresses synthesis of 1,25(OH)2D, 
and may decrease parathyroid hormone (PTH). PTH 
increases renal phosphate clearance and stimulates synthesis 
of 1,25(OH)2D
4). In chronic kidney disease (CKD) patients, 
ionizing calcium (iCa) is decreased secondary to phosphate 
Introduction
Vitamin D is known to be essential for bone metabolism. 
The number of peer-reviewed publications with the term 
‘vitamin D’ in their title or abstract has increased greatly 
since the early 2000s
1). PubMed currently lists over 25,000 
publications from 1950 to the present. In the 1960s, 
fewer than 100 papers on ‘vitamin D’ were published per 
year; however, in 2010, this rate of publication reached 
approximately 2,500 papers per year. This expansion of 
research over recent decades has resulted in a dramatic 
increase in our understanding of additional biological 
actions of vitamin D on various systems including pancreas 
β-cell function, immune, cardiovascular, muscle, and 
brain systems, and control of the cell cycle. An interesting 
relationship exists between mortality in ischemic heart 
disease and geographic latitude in European countries
2), 
which shows an increase in the mortality of heart 2      HS Kim et al. • Vitamin D, and Kidney Disease
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retention and decrease in 1,25(OH)2D. Phosphate retention 
increases FGF-23, which, in conjunction with its cofactor, 
Klotho protein, decreases the activity of 1α-hydroxylase 
and increases 24α-hydroxylase, thus decreasing the levels of 
circulating 1,25(OH)2D. Additionally, phosphate retention 
results in an increase in posttranscriptional synthesis of 
PTH. Decreases in the vitamin D receptor (VDR), calcium 
sensor receptor, and Klotho–FGFR1 receptor complex in 
the parathyroid gland aggravate the development of the 
secondary hyperparathyroidism in CKD patients
4). 
Apart from hyperparathyroidism, calcium and phosphate 
imbalance and vitamin D deficiency also contribute to 
vascular calcification. A cross-sectional study by Gracia-
Canton et al. has reported an independent negative 
association between serum levels of 25(OH)D and vascular 
calcification in 210 patients with stage 4 and 5 CKD
5). 
Plain X-ray images of pelvis, hands, and lateral lumbar 
spines from all subjects were studied for calculation of semi-
quantitative vascular calcification scores, as described by 
Adragao
6) and Kauppila
7). Adragao scores revealed only 
47 patients (22.4%) without vascular calcification and 
120 patients (57.1%) with scores higher than 3
5). Kauppila 
scores revealed only 29 patients (13.8%) without aortic 
calcifications and 114 patients (54.3%) with scores higher 
than 7
5). Higher vascular calcification scores were related 
to older age, diabetes, history of cardiovascular disease 
(CVD), and lower levels of 25(OH)D
5). Only one-fifth of 
patients had adequate levels of 25(OH)D, whereas a half 
had vitamin D insufficiency, and a quarter had vitamin 
deficiency (Fig. 1)
5).
Vitamin D and vitamin D receptor
Vitamin D is a multifunctional hormone that can af-
fect many essential biological functions, ranging from 
immune regulation to mineral ion metabolism. Calcitriol 
or 1,25(OH)2D is the active form of vitamin D, formed 
by dual hydroxylation in the liver and kidney. Figure 
2 shows a simplified diagram of the different stages 
of vitamin D synthesis
8). Vitamin D2 (ergocalciferol), 
which is absorbed mainly from food, and vitamin D3 
(cholecalciferol), produced in the skin by photolytic cleavage 
of 7-dehydrocholesterol, is transported to the liver and 
converted to 25(OH)D, the major circulating metabolite 
of vitamin D. The final activation step, 1-hydroxylation, 
occurs primarily, but not exclusively, in the kidney, forming 
1,25(OH)2D
8).
Active vitamin D metabolites exert biological activities 
25(OH)D 
< 15 ng/mL
25(OH)D 
15-30 ng/mL
25(OH)D 
> 30 ng/mL
20
10
0
V
a
s
c
u
l
a
r
 
c
a
l
c
i
f
i
c
a
t
i
o
n
 
s
c
o
r
e
Fig. 1. Prevalence of Vitamin D Deficiency and Vascular Calcification 
in Stage 4 and 5 CKD. CKD, chronic kidney disease; 25(OH)D, 25- 
hydroxyvitamin D; white box, Adragao score
6); gray box, Kauppila 
score
7).
*Data from the study of Garcia-Canton C et al. Ref. 5.
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Fig. 2. Synthesis of Vitamin D. D2, vitamin D2; D3, vitamin D3; VDR, 
vitamin D receptor. 
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mainly through the VDR
1). VDRs are operational in at 
least 38 tissues of the body. In these target tissues, VDR 
functions in the cell nucleus as a transcriptional factor 
influencing approximately 3% of the human genome, 
and in the plasma membrane caveolae as a modulator of 
signal transduction pathways (Fig. 3). The activity of the 
VDR conformational ensemble (with 2 ligand pockets) can 
generate either genomic or rapid biological responses. In 
this model, one shape (6-s-trans) of the conformationally 
flexible 1α,25(OH)2D can interact with VDR localized in 
the cell nucleus to generate genomic responses via regulation 
of gene transcription, whereas a different shape (6-s-cis) 
of 1α-25(OH)2D binds to the second ligand pocket of the 
VDR associated with caveolae of the plasma membrane to 
generate rapid responses
1). VDR activation through these 
pathways has been shown to have wide-ranging effects. 
Calciotropic functions of 1,25(OH)2D include physiological 
regulation of calcium transport and bone mineralization. 
Synthesis of circulating 1,25(OH)2D, which mediates these 
calciotropic actions, is tightly regulated. Non-calciotropic 
actions involve activation of VDRs by locally produced 
1,25(OH)2D in a number of tissues in a paracrine and 
autocrine fashion
9). In particular, vitamin D is closely linked 
to CVD
2). Experimental studies have shown that vitamin 
D treatment reduces neurohormonal activation, inhibits 
inflammation, and suppresses ventricular hypertrophy
10).
Vitamin D deficiency in CKD
The recent Workshop Consensus for Vitamin D Nutri-
tional Guidelines estimated that approximately 50% and 
60% of the older populations in North America and the 
rest of the world, respectively, do not have satisfactory 
vitamin D status
11). The consensus further concluded that 
the situation is similar in younger subjects. Reasons for 
this remain unclear but are probably related to factors 
such as urbanization, demographic shifts, decreased 
outdoor activity, air pollution, global dimming, and 
decrease in cutaneous production of vitamin D with age. 
Epidemiological investigations in many countries have 
shown high prevalence of unsatisfactory vitamin D status 
(Table 1)
12-15). In particular, the 2008 Korea National 
Health and Nutrition Examination Survey (KNHANES) 
found vitamin D insufficiency in 47.3% of male and 64.5% 
of female subjects
15). 
The outpatient cross-sectional cohort study conducted 
by Levin et al. has revealed that abnormalities of mineral 
metabolism occur early in CKD
16). A decrease in 
1,25(OH)2D3 + VDR (conformational ensemble)
Altered genomic responses 
Gene expression
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Signal transduction:
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G protein-coupled receptors, 
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Second messenger systems
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transcription
Fig. 3. Function of Vitamin D Receptor (VDR) Conformational Ensemble: Genomic or 
Rapid Responses. 
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1,25(OH)2D levels was above the range of glomerular 
filtration rate (GFR) values even in the early stage of CKD
16). 
Similarly, significant inverse correlations were observed 
among serum phosphate, FGF-23 and PTH levels, and 
GFR in patients with stage 1 to 3 CKD
17). Hypovitaminosis 
D is prevalent even in patients with early-stage CKD
18). It is 
consistent with the previous data that 25(OH)D deficiency 
worsens with the progression of CKD. Therefore, the 
Kidney Disease: Improving Global Outcomes (KDIGO) 
Clinical Practice Guidelines have recommended annual 
measurement of 25(OH)D and have also recommended 
that the level should be maintained at 30 ng/mL or higher 
in patients with any stage of CKD
19). 
Decreased VDR activation and clinical outcomes
Melamed et al. tested the association of low 25(OH)D 
levels with all-cause, cancer, and CVD mortality in 13,331 
nationally representative adults from the Third National 
Health and Nutrition Examination Survey (NHANES III) 
linked mortality files
20). In this cross-sectional multivariate 
analysis, increasing age, female sex, non-white race/
ethnicity, diabetes, current smoking, and higher body mass 
index were all independently associated with higher odds 
of 25(OH)D deficiency, whereas greater physical activity, 
vitamin D supplementation, and non-winter season showed 
an inverse association
20). In multivariate models, compared 
with the highest quartile, being in the lowest quartile for 
25[OH]D levels (< 17.8 ng/mL) was associated with a 26% 
increased rate of all-cause mortality (mortality rate ratio, 
1.26; 95% CI, 1.08–1.46) and a population attributable risk 
of 3.1%
20). The prospective cohort study by Dobnig et al., 
which enrolled patients undergoing diagnostic coronary 
angiography with normal kidney function showed a similar 
result with regard to relationships between endogenous 
25(OH)D and 1,25(OH)2D levels and all-cause and car-
diovascular mortality
21). Multivariate-adjusted hazard ratios 
(HRs) for patients with lower levels of 25(OH)D were two 
times higher for all-cause mortality and cardiovascular 
mortality
21).
A meta-analysis of randomized controlled trials by 
Autier and Gandini showed that intake of ordinary doses 
of vitamin D supplements appears to be associated with 
decreases in total mortality rates
22). They have identified 
18 independent randomized controlled trials, including 
57,311 participants. The relative risk for mortality from any 
cause was 0.93 (95% CI, 0.87–0.99)
22). Kandula et al. have 
reported on vitamin D supplementation in CKD by meta-
analysis
23). Among observational studies and randomized 
controlled trials, significant improvement was observed in 
serum 25(OH)D levels, along with an associated decline 
in PTH levels
23). A low incidence of hypercalcemia and 
hyperphosphatemia has been reported with vitamin D 
supplementation. However, included studies were mostly of 
low to moderate quality and did not show beneficial effects 
on hard clinical endpoints
23). Kovesdy et al. reported on the 
benefit of activated vitamin D treatment in patients with 
predialysis CKD
24). Two hundred fifty-eight of 520 subjects 
received treatment with calcitriol. The incidence rate for 
mortality and combined death and dialysis initiation was 
significantly lower in treated than in untreated patients. 
Treatment with calcitriol was associated with a trend 
toward a lower incidence of dialysis. These results were 
consistent across different subgroups
24).
One prospective cohort study of incident dialysis pa-
tients in the Netherlands (the NECOSAD) revealed an 
Table 1. Definition and Prevalence of Vitamin D Deficiency in the General Population
Nations US
12) Germany
13) New Zealand
14) Korea
15)
Participants N = 4,495 (age ≥ 20 yrs) N = 7,124 (age ≥ 18 yrs) N = 2,946 (age ≥ 15 yrs) N = 6,529 (age ≥ 20 yrs)
Definition 25(OH)D ≤ 20 ng/mL 25(OH)D ≤ 20 ng/mL 25(OH)D ≤ 20 ng/mL 25(OH)D ≤ 20 ng/mL
Prevalence 41.6% 57.3% 48% 54.3%
Mean 25(OH)D (ng/mL) 20.1/19.9 18.08/17.88 20.8/18.8 22.36/18.52
Survey 2005-2006 1997-1999 1996-1997 2008
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association of vitamin D deficiency in dialysis patients 
with an adverse health outcome, in particular, with short-
term cardiovascular mortality
25). Teng et al. reported on 
a historical cohort study of activated injectable vitamin D 
and hemodialysis survival
26). During a 2-year observational 
period, 37,173 patients on hemodialysis received activated 
injectable vitamin D, and 13,864 did not. At 2 years, the 
mortality rate was 13.8/100 person-years in the group that 
received injectable vitamin D, compared with 28.6/100 
person-years in the non-vitamin D group (P < 0.001). 
The incidence of cardiovascular-related mortality was 
7.6/100 person-years in the injectable vitamin D group, 
compared with 14.6/100 person-years in the non–vitamin 
D group (P < 0.001). The study by Wolf et al. also showed 
that, although low vitamin D levels were associated with 
increased mortality, significant interactions were noted 
among vitamin D levels, subsequent active vitamin D 
therapy, and survival
27). Compared with patients with 
the highest 25(OH)D or 1,25(OH)2D levels who received 
therapy, untreated deficient patients showed a significantly 
increased risk for early mortality
27) (Table 2).
Summary
In summary, vitamin D deficiency is common not 
only in CKD patient but also in the general population. 
Reduced VDR activation occurs early in CKD. Low 
25(OH)D is a risk factor for and is predictive of cardio-
vascular events. Decreased VDR activation is a major 
pathophysiological factor in the development of secondary 
hyperparathyroidism and also contributes to CKD mor-
bidity and mortality. Patients with CKD have reduced VDR 
activation. Restoration of the physiology of VDR activation 
should be essential therapy for CKD patients.
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